Literature DB >> 4083866

In vitro activity of carumonam.

R J Fass, V L Helsel.   

Abstract

The in vitro activities of carumonam and eight comparative antimicrobial agents were studied. MICs of carumonam were less than or equal to 0.5 microgram/ml for 91% of members of the family Enterobacteriaceae and less than or equal to 16 micrograms/ml for 88% of nonfermenters; gram-positive cocci and anaerobic bacteria were resistant. Combinations of carumonam with piperacillin, nafcillin, or clindamycin were usually indifferent, although synergy between carumonam and piperacillin was observed with 20 (13%) of 155 strains.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4083866      PMCID: PMC180340          DOI: 10.1128/AAC.28.6.834

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  3 in total

1.  In vitro activities of Ro 17-2301 and aztreonam compared with those of other new beta-lactam antibiotics against clinical isolates of Pseudomonas aeruginosa.

Authors:  W W Ng; P Y Chau; Y K Leung; D M Livermore
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

2.  In vitro and in vivo antibacterial activities of carumonam (AMA-1080), a new N-sulfonated monocyclic beta-lactam antibiotic.

Authors:  A Imada; M Kondo; K Okonogi; K Yukishige; M Kuno
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

3.  In vitro activities of beta-lactam and aminoglycoside antibiotics. A comparative study of 20 parenterally administered drugs.

Authors:  R J Fass
Journal:  Arch Intern Med       Date:  1980-06
  3 in total
  4 in total

1.  Susceptibility testing of carumonam: interpretive criteria for 30-microgram disk tests and quality control guidelines for disk diffusion and broth microdilution methods.

Authors:  R N Jones; A L Barry
Journal:  J Clin Microbiol       Date:  1987-11       Impact factor: 5.948

2.  In vitro activity of carumonam (Ro 17-2301; AMA-1080) versus enteropathogenic and nonfermentative gram-negative rods and Legionella pneumophila.

Authors:  P Hohl; A von Graevenitz; J Zollinger-Iten
Journal:  Antimicrob Agents Chemother       Date:  1988-10       Impact factor: 5.191

3.  Carumonam versus ceftazidime for urinary tract infections.

Authors:  H Edelstein; S Oster; K Cassano; R McCabe
Journal:  Antimicrob Agents Chemother       Date:  1988-07       Impact factor: 5.191

4.  Carumonam enhances reactivity of Escherichia coli with mono- and polyclonal antisera to rough Escherichia coli J5.

Authors:  B P Overbeek; J F Schellekens; W Lippe; B A Dekker; J Verhoef
Journal:  J Clin Microbiol       Date:  1987-06       Impact factor: 5.948

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.